Medigene is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases.

Research Grants 19 show all


$400.7K
2015

$1.2M
2016

$1.1M
2017

$95.3K
2018

$95.3K
2019

Publications 13 show all

  • 4
    Receptors, Antigen, T-Cell/chemistry
  • 3
    Receptors, Antigen, T-Cell/immunology
  • 2
    Immunotherapy/methods
  • 2
    Peptides/immunology
  • 2
    T-Lymphocytes/immunology
  • 1
    Antibodies, Monoclonal/chemistry
  • 1
    Antigens, Neoplasm/analysis
  • 1
    Antirheumatic Agents/therapeutic use
  • 1
    Arthritis, Rheumatoid/drug therapy
  • 1
    B7-1 Antigen/drug effects

Patents 1,194show all

  • 365
    A61K - Preparations for medical, dental, or toilet purposes
  • 274
    C07K - Peptides
  • 197
    C12N - Microorganisms or enzymes
  • 106
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 93
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 53
    Y02A - Technologies for adaptation to climate change
  • 42
    A61M - Devices for introducing media into, or onto, the body
  • 25
    C07D - Heterocyclic compounds
  • 18
    B82Y - Specific uses or applications of nanostructures
  • 15
    C40B - Combinatorial chemistry

Clinical Trials 26show all

8N/A5Phase 15Phase 1/Phase 23Phase 23Phase 32Other

Contact Information

Planegg
Germany